Manulife Financial (MFC.TO) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Manulife Financial (MFC.TO)

60.02

-0.65 (1.07%)

as of Jul 23, 2026, 1:59:53 pm Market Open.

1632 watching

Investor Insights

Jul 22, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Manulife Financial (MFC) has garnered a mostly positive outlook among various experts, highlighting its competitive positioning within the Canadian financial sector, particularly in comparison to major banks like TD and SLF. Analysts note MFC's ongoing strength in wealth management and healthy growth prospects in Asia, although there are concerns regarding its current valuation, as it trades over 2x book value and exhibits only moderate earnings growth. Despite being classified as slightly overbought, its charts remain healthy, with many recommending caution yet seeing potential for growth in the long run. The company's strong dividend yield and management strategies, particularly in alternative investments, also contribute to a favorable long-term investment story, although short-term volatility may present opportunities for those willing to enter at lower price points.

Consensus

Positive

Valuation

Fair Value

Similar

SLF,SLF

BUY ON WEAKNESS

Defensive, modest beats, clean last quarter, doing well in Asia, incredibly cheap, decent growth rate. Sort of like that cough syrup commercial, "You might not like it, but it works." Has severely underperformed. Accounting standards headwinds. Trades at 6x with a 10% growth rate. Whippy stock, you can probably purchase under $25 or 24.50.

Wealthica Track your Stocks in your Watch List

SELL ON STRENGTH

Allan Tong’s Discover Picks MFC pays a safe dividend, too (at a 32.98% payout ratio), but it’s even higher at 5.16%. Mind you, the street has a bullish forward PE of 11.91x on SLF, so the street believes in the company’s growth. Profit margins of both insurers are virtually the same around 11.5%, but MFC trades at a lower PE of 7.3x. However, MFC shares can never breach $28, despite consistent price targets as high as $30. Why, I don’t know, but the charts are there to see. Read 4 Promising TSX Stocks for our full analysis.

HOLD

Good company, nice dividend. Asian franchise is really strong, which will add growth over the long term, but is adding volatility right now. Not paying a lot for it, either on PE or price to book. Nice story to have.

HOLD

Sell MFC and buy BNS? Is watching the impact of Hong Kong on MFC. She prefers owning Canadian banks to lifecos. MFC trades at a discount to the group. Manager continue to rectify past company mistakes. The dividend is safe. She does own BNS.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O’Reilly As a quality Canadian company with growing sales volumes, favourable interest rates, and disciplined expense management, we reiterate MFC as a TOP PICK. A favorable product mix, higher margins in annuities and international business are expected to drive future value. It pays a great dividend, backed by a payout ratio under 35% of cash flow. We continue to recommend a stop at $21, looking to achieve $30.50 — upside potential over 23%. Yield 5.2% (Analysts’ price target is $30.31)

TOP PICK

Value name. One of the world's largest lifecos. Asia represents 50% revenue, middle class is growing. Aging global population needs wealth management services. Rising interest rates. Just under 1x price to book, significant discount to peers. Dividend should grow moderately, plus nice capital appreciation. Yield is 5.22%. (Analysts’ price target is $31.70)

PAST TOP PICK

(A Top Pick Jan 11/21, Up 20%) Likes it still, especially with rising interest rates. Lifecos will earn more on their spreads. Still on the cheap side.

BUY

MFC vs. SLF MFC is cheaper, better yield. Rising rates are good for insurance companies broadly, and MFC in particular. Long-term chart shows it has traded higher under normal interest rates conditions. Mild preference for MFC.

BUY

More value right now in lifecos than in banking. GWO is his favourite for the management and capital allocation. But MFC and SLF are both good. MFC is repositioning itself, releasing excess capital. Fundamentally undervalued. Trades at 8x normalized earnings. You could buy and hold for the long term.

WEAK BUY

Caller owns 7,000 shares You should diversify. MFC trades at a discount to the group because it has issues, but management is dealing with that. She expects MFC to catch up, but she is reassessing MFC. She hears how the younger people are leaving Hong Kong, which could dampen MFC's growth in that region.

TRADE

Has had a good run and beat on the 4th quarter. Asia component is good and it is cheap at 6.84 times with 11% growth rate. Concerns relate to long term care component along with new accounting standards. Not buying long. Recommends keeping cash for more opportunities.

BUY

Not sure why so cheap. Trades at a deep discount at only 7X core P/E and earnings are growing. Great dividend yield and is a value oriented play.

BUY

Manulife vs. SunLife He prefers Manulife, though there are concerns about their Asian exposure. But they are selling at slightly over book and SLF higher. MFC also pays a higher yield of over 1%, and the valuation is better with MFC. He owns both and both will benefit from rising interest rates. MFC has been minimizing risk by getting out of their non-core holdings and to concentrate on their profitable businesses, but this demands patience. They are making solid progress as the new CEO focuses on shareholder value.

WEAK BUY

Why trading at a discount to GWO and SLF? Historically, MFC has stumbled, like CIBC in banking. That's why. But all insurers will benefit from higher interest rates, no doubt. So, MFC is not a bad buy at the moment. Among financials, he prefers banks; insurers have to ensure that their assets match their liabilities, so they are more conservative.

BUY ON WEAKNESS

Allan Tong’s Discover Picks As a trade or a medium-term hold, Manulife benefits from rising interest rates and pays a generous 5.22% dividend. It trades at only a 7.27x PE. In the past seven years, MFC tends to plateau slightly above $27 and fails to rise to $28. With the street expecting four rate hikes in 2022, MFC has another shot at cracking at $28. Since Dec. 1, 2021, Manulife has climbed $2 on the tailwind of rising rate talk. Read 3 Oversold Stocks to Buy Right Now for our full analysis.

Showing 196 to 210 of 2,283 entries

Most Recent Experts

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Jim Cramer - Mad Money

CNBC

John Stephenson

Stephenson & Company Capital Management

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Julien Nono-Womdim

Goodreid Investment Council

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Manulife Financial (MFC.TO)